CHICAGO — Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus trastuzumab and pertuzumab across patients with HER2-positive ...

WILMINGTON, Del., June 02, 2025--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

TOKYO & BASKING RIDGE, N.J., June 02, 2025--ENHERTU plus Pertuzumab Reduced Risk of Disease Progression or Death by 44% vs. THP as 1L Therapy in Patients w/ HER2 positive mBC in DESTINY-Breast09 ...

The breast cancer drug pertuzumab when added to Herceptin improved the treatment of women with early-stage, HER-2 positive breast cancer, researchers reported Friday at the annual meeting of the ...

Enhertu® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line ...

People who received pertuzumab in combination with trastuzumab and chemotherapy experienced a 38% reduction in the risk of their disease worsening or death (progression-free survival, or PFS), (HR ...

Pertuzumab is a monoclonal antibody being studied in early-stage and metastatic HER2-positive breast cancer. It is an investigational HER2-targeted medicine called a HER2 dimerization inhibitor (HDI).

Pertuzumab is a humanized monoclonal antibody being studied in early and advanced stages of HER2-positive breast cancer and advanced HER2-positive gastric cancer.

4.5 The committee heard from the clinical experts that pertuzumab with trastuzumab and docetaxel is a very effective treatment, and has been shown to improve overall survival by approximately 16 ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line ...